Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA.
City & State:Cambridge,Massachusetts
No of Employees:
Revenue:
Public/Private:
Corporate Video Link:
Join our 10,000+ subscribers and get access to the latest templates, freebies, announcements and resources!